13 completed, 1 active not recruiting, 1 terminated. 7 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Active not recruiting 1 |
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
Follow Alkylating Agent-Related Acute Myeloid Leukemia: new trials by email Literature Review of Alkylating Agent-Related Acute Myeloid Leukemia trials Research Report on Alkylating Agent-Related Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission Laboratory Biomarker Analysis, Lenalidomide - Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 29 | 2014-11-13 | 2022-11-14 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2013-07-30 | 2022-07-22 |
| Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Erlotinib Hydrochloride, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 2 | Completed | M.D. Anderson Cancer Center | 29 | 2013-05-16 | 2020-01-07 |
| Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Cytarabine, CHK1 Inhibitor SCH 900776, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2013-05-01 | 2016-09-01 |
| Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Cytarabine, Daunorubicin Hydrochloride, Decitabine - Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 178 | 2011-09-16 | 2026-04-27 |
| Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Tipifarnib, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2011-05-01 | 2015-04-08 |
| Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Adult Acute Monoblastic Leukemia | Phase 3 | Completed | Children's Oncology Group | 517 | 2011-04-04 | 2021-03-30 |
| Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia Azacitidine, Etoposide, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 13 | 2010-12-01 | 2015-08-20 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2010-11-24 | 2017-09-25 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 68 | 2010-07-15 | 2022-08-04 |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 66 | 2010-06-04 | 2025-11-20 |
| Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Lenalidomide, Cytarabine, Idarubicin - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 61 | 2010-05-01 | 2014-12-23 |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Azacitidine, Entinostat, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 197 | 2006-08-01 | 2017-02-02 |
| Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia Sorafenib Tosylate - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2005-10-01 | 2015-04-28 |
| Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Clinical Observation, Tipifarnib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia | Phase 3 | Completed | National Cancer Institute (NCI) | 144 | 2004-08-18 | 2026-07-14 |
Leukemia, Myeloid, Acute (13) · Leukemia, Myelomonocytic, Acute (13) · Leukemia, Monocytic, Acute (8) · Leukemia, Erythroblastic, Acute (6) · Leukemia, Megakaryoblastic, Acute (6) · Leukemia, Promyelocytic, Acute (5) · Leukemia, Myelomonocytic, Chronic (4) · Leukemia, Basophilic, Acute (3) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Anemia, Refractory, with Excess of Blasts (2) · Burkitt Lymphoma (2) · Leukemia, Eosinophilic, Acute (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Blast Crisis (1)
Hematologic Diseases (14) · Hemic and Lymphatic Diseases (14) · Leukemia, Myeloid (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Leukemia (13) · Bone Marrow Diseases (10) · Chronic Disease (6) · Disease Attributes (6) · Myeloproliferative Disorders (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Myelodysplastic-Myeloproliferative Diseases (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3)
Azacitidine (3) · Cytarabine (3) · Lenalidomide (3) · Decitabine (2) · Injections (2) · tipifarnib (2) · 4-demethoxydaunorubicin bis(hydrazone) (1) · Antilymphocyte Serum (1) · Busulfan (1) · Caspofungin (1) · Daunorubicin (1) · Erlotinib Hydrochloride (1) · Etoposide (1) · Fluconazole (1) · Idarubicin (1)
National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (2) · Children's Oncology Group (1) · Roswell Park Cancer Institute (1)
United States (14) · Canada (2) · Israel (1) · Peru (1) · Puerto Rico (1)
Jorge Cortes (2) · B. Smith (1) · Elizabeth Griffiths (1) · Ivana Gojo (1) · Jeffrey Lancet (1) · Joseph Brandwein (1) · Joseph M Scandura (1) · Leslie Andritsos (1) · Ravi Vij (1) · Selina Luger (1) · Steven Gore (1) · Tapan M Kadia (1) · Theoklis E Zaoutis (1) · William Blum (1)
PMID 20952518, PMID 26577691, PMID 31212080, PMID 31688884, PMID 32777116
U01CA070095 (3), N01CM00071 (2), P30CA006973 (2), P30CA016058 (2), P30CA016672 (2), U01CA076576 (2), U10CA021115 (2), U10CA180820 (2), N01CM00032 (1), N01CM00070 (1), N01CM00100 (1), N01CM62201 (1), N01CM62203 (1), N01CM62204 (1), N01CM62209 (1)